Stille AB: Interim Report Q2 2022
Stille AB (publ) publishes the interim report for the second quarter and first half-year of 2022. ”Strong growth and significantly improved profits.”, summarizes Hanna Ernestam Wilkman, Stille’s CEO.
Revenues increased by 56 percent to 63.3 MSEK (40.6) and the organic growth amounted to 14 percent with revenues of 46.1 MSEK. Operating profit increased by 72 percent 8.9 MSEK (5.2).
Compared to the same quarter last year, business unit Surgical Instruments doubled its revenue driven by the acquired volume of S&T. For the same period, business unit Surgical Tables increased sales by 25 percent.
”The high demand for OR-related products continues to generate significant growth. Our continuous adjustments to price and delivery terms in combination with a stable development of OPEX, has resulted in substantially improved profitability”, says Hanna Ernestam Wilkman.
”I am proud of our ability to deliver a quarter with such strong growth and profitability despite issues in the supply chain. While these challenges are expected to continue, I am very optimistic of the company’s future.”, concludes Stille’s CEO.
| MSEK | apr-jun 2022 |
apr-jun 2021 |
jan-jun 2022 |
jan-jun 2021 |
jul-jun 2021/22 |
jan-dec 2021 |
| Revenue | 63.3 | 40.6 | 124.9 | 76.4 | 235.6 | 187.1 |
| Gross Profit Margin, % | 45.4 | 45.4 | 45.1 | 43.8 | 45.1 | 44.6 |
| Operating Profit | 8.9 | 5.2 | 16.4 | 9.1 | 27.4 | 20.1 |
| Operating Profit, % | 14.0 | 12.7 | 13.2 | 12.0 | 11.6 | 10.7 |
| EBITDA | 11.2 | 6.6 | 21.0 | 11.8 | 42.6 | 26.8 |
| Net Income | 7.8 | 2.7 | 13.1 | 6.8 | 22.5 | 16.1 |
Torshälla, July 15th, 2022.
This information is such information that Stille AB is obliged to disclose according to the EU’s market abuse regulation. The information was, through the agency of the contact person above, rendered for publication on July 15th, 2022, kl. 08.00 (CET).
For more information, please contact:
Hanna Ernestam Wilkman
CEO and President
+46 (0)72 402 10 88 | hanna.e.wilkman@stille.se
Stille AB (publ) publ) develops, manufactures and markets medical devices for surgeons across the world. Stille was founded in 1841 and is one of the world’s oldest medical device companies. Stille’s main business areas are surgical instruments and c-arm tables. Stille’s surgical instruments are mostly used during different kinds of open surgery. During minimal invasive procedures. the c-arm tables imagiQ2 and Medstone are key products. The company has a strong brand and products of a renowned high-quality. The share is listed on First North Growth Market under the acronym “STIL” with Eminova AB as Certified Adviser, Eminova Fondkommission AB, + 46 8 684 211 10, adviser@eminova.se. For more information, visit www.stille.se.